Our Head of Molecular Technologies, Dr Martin Main, has been invited to serve as a member of the SLAS Discovery Editorial Board and joins our Chief Scientific Officer, Dr Peter Simpson, previously elected to SLAS’ Board of Directors in November 2017.
SLAS Discovery focused on Advancing Life Sciences R&D is one of two journals published by the Society for Laboratory Automation and Screening (SLAS). A non-profit, mission-driven Society, working to advance research through the use of technology. Serving a global membership base of more than 18,000 professional and aspiring scientists from industry, academia and government institutions
During his three-year term that begins in June 2018, Martin will join the Editorial Board assisting identification of high-quality contributors as well as provision and review of authored manuscripts.
In his current role as Head of Molecular Technologies, Martin leads a team that is responsible for establishing and applying novel technology platforms that are aligned to the Catapult’s strategic science focus areas of complex cell models, target engagement, biomarkers and drug delivery. Prior to joining the Catapult, Martin worked in the pharmaceutical industry for 24 years, at Merck, GlaxoSmithKline and AstraZeneca.
Dr Martin Main, Head of Molecular Sciences at Medicines Discovery Catapult, says:
“The purpose of SLAS is to advance life science discovery and technology through education, serving as a public forum for the exchange of information. This focus on discovery, innovation and collaboration is aligned to the aims of the Medicines Discovery Catapult. I am therefore proud to contribute to the SLAS Discovery journal as part of the Editorial Board.”
